Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2023-10-23 00:00:00 ET · period of report 2023-10-19 · accession 0001209191-23-053351 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-23 | 2023-10-19 | RARE | KAKKIS EMIL D | Pres, CEO, Dir | M - OptEx | $6.86 | +47.9K | 647.0K | +8% | +$328.3K |
| D | 2023-10-23 | 2023-10-19 | RARE | KAKKIS EMIL D | Pres, CEO, Dir | S - Sale+OE | $33.52 | -47.9K | 599.7K | -7% | -$1.60M |
| D | 2023-10-23 | 2023-10-19 | RARE | KAKKIS EMIL D | Pres, CEO, Dir | M - OptEx | $0.00 | -47.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-19 | M | A | 47,853 | $6.86 | 647,029 | D | — | — | (F1) The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. |
| 2 | Common | Common Stock | 2023-10-19 | S | D | 47,853 | $33.52 | 599,743 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F4) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. (F3) Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-10-19 | M | D | 47,853 | $0.00 | 0 | D | $6.86 · — to 2023-11-01 | 47,853 Common Stock | (F5) The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date. |